ArticleMolecular and cellular biochemistry2026
Nutrient deprivation enhances the cytotoxic effects of a sulfonamide-chalcone hybrid in PC-3 prostate cancer cells.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid molecules integrating different pharmacophoric motifs have emerged as a promising strategy in anticancer drug discovery. In this study, we report for the first time the biological effects of a sulfonamide-chalcone hybrid in the PC-3 prostate cancer cell line under standard culture conditions and nutrient deprivation. The molecular design of SSC185 (µ-(2,5-dichloro-N-{4-[(3E)-4-(3-nitrophenyl)buta-1,3-dien-2-yl]phenyl}benzenesulfonamide) incorporates an α,β-unsaturated system conjugated to the chalcone scaffold together with a sulfonamide moiety, structural features frequently associated with modulation of cancer-related signaling pathways. Results demonstrated that SSC185 reduced the MTT signal of PC-3 cells in a concentration- and time-dependent manner, with IC₅₀ values of 24.69 µM at 24 h and 18.9 µM at 72 h, and exhibited enhanced activity under serum-deprived conditions, with an IC₅₀ of 4.20 µM. Complementary studies employing pharmacological modulators of autophagy, apoptosis, redox status, and proteostasis were conducted to further characterize the compound's activity. SSC185 increased SQSTM1/p62 and LC3B-I levels without detectable changes in LC3B-II levels or increased acidic vesicle formation, accompanied by reduced AKT/RPS6 signaling and mitochondrial dysfunction. These molecular alterations were associated with the cellular response to SSC185, while nutrient deprivation markedly enhanced its activity in PC-3 cells, indicating that the cellular nutritional context influences the response to the compound.
Indexed as
Identifiers
42726371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.